What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GLP-1 receptor agonist
PeptideXpo buyer fit
This PeptideXpo page supports buyers comparing Semaglutide as part of a wider metabolic-peptide catalog. The commercial question is not only whether Semaglutide is available; it is whether the supplier can support related GLP-1, amylin, blend, and fill-size programs under one procurement relationship.
Overview
Semaglutide is a 31-amino-acid synthetic GLP-1 receptor agonist with two engineered substitutions and a C18 fatty-diacid moiety on Lys26 that drives reversible albumin binding and the once-weekly pharmacokinetic profile. As an active ingredient, Semaglutide is the basis of multiple FDA-approved finished drugs: Ozempic (type 2 diabetes, subcutaneous), Wegovy (chronic weight management, subcutaneous), and Rybelsus (type 2 diabetes, oral with SNAC absorption enhancer). PeptideXpo supplies lyophilized Semaglutide acetate at ≥99.0% HPLC purity with batch-specific COA: peak-integration HPLC, ESI mass spec within 0.5 Da of theoretical (4113.58 g/mol average), water content by Karl Fischer, and counter-ion. LAL endotoxin and USP <61>/<62> microbial limits are available as add-on testing on the same lot, the recommended scope for 503A and 503B compounding pharmacy workflows and for in vivo research. Seven standard vial fills (2 mg through 50 mg) cover both research aliquot scales and dispensing workflows; sterile-filled vials and custom OEM fills are routine through the OEM service. Buyers building pre-formulated CagriSema (Cagrilintide + Semaglutide) blends should reference the dedicated CagriSema SKU rather than co-mixing in solution, co-lyophilized blends preserve potency better than solution-phase mixing.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Finished Semaglutide drug products (Ozempic, Wegovy, Rybelsus) are FDA-approved; the bulk active itself is not on the 503A bulks list as of the current cycle. Compounding eligibility depends on the destination market's current shortage / regulatory posture, which buyers are responsible for verifying at the time of dispense.
Frequently asked questions
Semaglutide is a 31-amino-acid GLP-1 analog with three engineered features: (1) the Ala8→Aib substitution at position 8 that resists DPP-4 cleavage, (2) a Lys34→Arg substitution that prevents off-target lipidation during synthesis, and (3) a C18 fatty-diacid (γGlu-2xOEG linker) attached at Lys26 that drives reversible albumin binding. The albumin-binding interaction is what extends plasma half-life from minutes (native GLP-1) to roughly a week, enabling once-weekly subcutaneous dosing. The same engineering principles inspired Tirzepatide and Retatrutide, though their linker geometries and fatty-acid chain lengths differ.
Both contain the same Semaglutide API, the difference is the finished formulation. Subcutaneous formulations (Ozempic, Wegovy) deliver Semaglutide directly into the subcutaneous tissue with predictable absorption. Oral Semaglutide (Rybelsus) is co-formulated with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), a permeation enhancer that locally raises pH in the stomach and protects Semaglutide from proteolysis while temporarily increasing gastric epithelial permeability. The bulk active PeptideXpo supplies is suitable for compounding into either presentation, subject to the receiving formulator's regulatory and stability work.
Semaglutide reconstitutes in bacteriostatic water for injection (BWFI) for multi-use research workflows, or in sterile water for injection (SWFI) for sterile single-use preparations. The lyophilizate dissolves within 60 seconds with gentle swirl, do not vortex, since the resulting foam entrains air and accelerates surface-mediated aggregation. Working solutions should be aliquoted into single-use volumes and held at -20 °C; the dominant in-lab degradation pathway is freeze-thaw cycling rather than slow temperature drift, so the operational guidance is thaw once, use, refreeze the remainder no more than two more times.
Related peptides
GIP / GLP-1 dual receptor agonist
GIP / GLP-1 / glucagon tri-agonist
Long-acting amylin analog
